<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577368</url>
  </required_header>
  <id_info>
    <org_study_id>PiperTazo</org_study_id>
    <secondary_id>2010-024606-34</secondary_id>
    <nct_id>NCT01577368</nct_id>
  </id_info>
  <brief_title>Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa</brief_title>
  <acronym>PiperTazo</acronym>
  <official_title>Efficacy and Safety of Piperacillin-Tazobactam Continuous Infusion vs Intermittent Infusion for Complicated or Nosocomial Pseudomonas Aeruginosa Infection or Suspected Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministerio de Sanidad y Política social</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen Macarena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Son Espases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Son Llatzer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Complejo Hospitalario de Especialidades Juan Ramón Jimenez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Virgen de las Nieves</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General de Cataluña</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Infanta Sofia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Ntra. Sra. de La Candelaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to verify that the administration of piperacillin / tazobactam
      administered by continuous infusion to treat complicated infections or with known or
      suspected nosocomial isolation of Pseudomonas aeruginosa is superior in efficacy to a 30%
      higher dose administered in conventional short infusion.

      The secondary objectives were compared between the following variables:

        -  Microbiological response at 3 days of starting treatment

        -  Time to microbiological cure

        -  Clinical response at 3 days of starting treatment

        -  Time to achieve defervescence

        -  To examine the relationship between pharmacokinetic variables and parameters of efficacy
           and safety

        -  To test the hypothesis that continuous infusion maintains adequate plasma drug levels
           compared with levels achieved with intermittent administration.

        -  Cost-effectiveness analysis

        -  Occurrence of adverse effects

      To this end, we designed a multicenter, randomized, controlled, double blind, comparing both
      forms of administration in patients with complicated or nosocomial infection with or without
      isolation of Pseudomonas aeruginosa.

      Patients who are candidates for inclusion are classified according to APACHE II and to have
      or not isolation of Pseudomonas aeruginosa. Subsequently be randomized to receive
      piperacillin-tazobactam by continuous infusion or short. Primary endpoint was measured as the
      ultimate effectiveness of treatment and other variables such as high efficiency, safety,
      pharmacokinetic and pharmacoeconomic.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with satisfactory clinical response (cure or improvement) at the end of Piperacillin-Tazobactam treatment</measure>
    <time_frame>14 days</time_frame>
    <description>Clinical cure: complete resolution of all signs and symptoms of infection
Clinical improvement: resolution or improvement of most signs and symptoms of infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical response (cure or improvement) at 3 days</measure>
    <time_frame>3 days</time_frame>
    <description>Clinical cure: complete resolution of all signs and symptoms of infection
Clinical improvement: resolution or improvement of most signs and symptoms of infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with microbiological response</measure>
    <time_frame>3 days</time_frame>
    <description>- Microbiological response: bacteriological eradication of causative organisms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to defervescence</measure>
    <time_frame>14 days</time_frame>
    <description>- Time to the abatement of fever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical cure</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with adverse effects</measure>
    <time_frame>14 days &amp; 60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Pseudomonas Aeruginosa Infection</condition>
  <arm_group>
    <arm_group_label>Piperacillin continuous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Piperacillin intermittent infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Piperacillin-Tazobactam 4gr intermittent infusion 4gr every 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin-Tazobactam continuous infusion</intervention_name>
    <description>Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours (DAY 1-14)</description>
    <arm_group_label>Piperacillin continuous infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin-Tazobactam intermittent infusion</intervention_name>
    <description>Piperacillin-Tazobactam intermittent infusion 4gr every 8 hours (DAY 1-14)</description>
    <arm_group_label>Piperacillin intermittent infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Complicated or Nosocomial Pseudomonas Aeruginosa Infection or Suspected Infection

          -  &gt; 18 years and &gt; 40 kg

          -  Negative pregnancy test for women within fertile period

          -  Informed consent signature

        Exclusion Criteria:

          -  Life expectancy &lt; 72 hr

          -  Central Nervous System (CNS) infection

          -  Ventilator-associated pneumonia

          -  Severe Neutropenia (&lt;500 cells/ml)

          -  Acinetobacter baumannii or extended spectrum beta lactamase (ESBL) suspected infection

          -  Cystic fibrosis

          -  Shock

          -  Creatinine clearance &lt; 20 ml/min

          -  Dialysis or hemoperfusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2012</study_first_posted>
  <last_update_submitted>September 19, 2014</last_update_submitted>
  <last_update_submitted_qc>September 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pseudomonas</keyword>
  <keyword>Piperacillin</keyword>
  <keyword>Beta-lactams</keyword>
  <keyword>Continuous infusion</keyword>
  <keyword>Intermittent infusion</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

